This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
Whitbread (WTB) - Agreed to sell Costa for £3.9bn to Coca-Cola; to return most of proceeds and cut debt. Closing price: 4,020p (Source: DowJones Newswires)
AstraZeneca (AZN) - Phase III trial for Anifrolumab treatment for lupus erythematosus unsuccessful. Closing price: 5,910p (Source: DowJones Newswires)
Sage Group (SGE) - CEO to step down; CFO to take additional role of interim COO; trading in line with previous FY guidance (revenues +7% organic, 27.5% organic op margin), but achievement still dependent on closing a number of Enterprise Management opportunities in Sept; Closing price: 645.6p (Source: DowJones Newswires)
BHP Billiton (BLT) - In investor briefing, CFO says underlying business going well, bullish on China; Shale sale on-track, cash to be returned by year-end; productivity gains should underpin dividend growth; plans to keep conservative strong balance sheet which suggests no big M&A on the horizon. Closing price: 1,666.2p (Source: DowJones Newswires)
(Sources: Company newswires, Bloomberg, CNBC, FT, Reuters, Wall Street Journal)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| SSE | SSE | -0.6% | -0.4% | -1.1% |
| ASTRAZENECA | AZN | -0.1% | 0.0% | -1.3% |
| HAYS | HAS | -4.0% | 0.9% | -5.1% |
| HUNTING | HTG | 9.1% | 13.5% | 2.2% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.
Prepared by Michael van Dulken, Head of Research